BioSpace News Archive

Alveo Technologies, Inc. announced a partnership with NYtor B.V, an innovative assay developer, to create a rapid, accurate, pen-side test that will detect the dominant swine flu strains, including H1N1, H1N2 and H3N2.

Epitel, a leader in AI technologies for patient-focused brain health solutions, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearances for two new innovative technologies: REMI™ Remote EEG Monitoring System for Ambulatory (at home) use and REMI Vigilenz™ AI For Event Detection.

CEL-SCI Corporation announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy.

Clarapath, a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, MD.

RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).

The University of Toronto’s Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs.

Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.

SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024.